UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 139

Sortiert nach

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

Breast cancer research and treatment, 2013-08, Vol.141 (1), p.13-22

2013

Link zum Volltext

Verfügbarkeit prüfen

Real-world treatment patterns and economic burden of post-cataract macular edema

BMC ophthalmology, 2023-09, Vol.23 (1), p.1-380, Article 380

2023

Link zum Volltext

Verfügbarkeit prüfen

Economic Evaluation of Tocilizumab Monotherapy Compared to Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis

Value in health, 2015-03, Vol.18 (2), p.173-179

2015

Link zum Volltext

Verfügbarkeit prüfen

Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy

Value in health, 2019-09, Vol.22 (9), p.988-994

2019

Link zum Volltext

Verfügbarkeit prüfen

HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales

Journal of managed care & specialty pharmacy, 2020-09, Vol.26 (9), p.1162

2020

Link zum Volltext

Verfügbarkeit prüfen

Performance-Based Risk-Sharing Arrangements: An Updated International Review

PharmacoEconomics, 2017-10, Vol.35 (10), p.1063-1072

2017

Link zum Volltext

Verfügbarkeit prüfen

Performance-based risk-sharing arrangements for devices and diagnostics in the United States: a systematic review

Journal of managed care & specialty pharmacy, 2022-01, Vol.28 (1), p.78

2022

Link zum Volltext

Verfügbarkeit prüfen

How Much Does the US Public Value Equity in Health? A Systematic Review

Value in health, 2023-03, Vol.26 (3), p.418-426

2023

Link zum Volltext

Verfügbarkeit prüfen

Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing

Journal of managed care & specialty pharmacy, 2017-10, Vol.23 (10), p.1010

2017

Link zum Volltext

Verfügbarkeit prüfen

Estimating the Cost-Effectiveness of OnabotulinumtoxinA for Neurogenic Detrusor Overactivity in the United States

Clinical therapeutics, 2013-04, Vol.35 (4), p.414-424

2013

Link zum Volltext

Verfügbarkeit prüfen

The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer

Value in health, 2009, Vol.12 (1), p.20-27

2009

Link zum Volltext

Verfügbarkeit prüfen

Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study

Value in health, 2024-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study

PharmacoEconomics, 2020, Vol.38 (1), p.57-68

2020

Link zum Volltext

Verfügbarkeit prüfen

Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis

Journal of managed care & specialty pharmacy, 2023-08, Vol.29 (8), p.917

2023

Link zum Volltext

Verfügbarkeit prüfen

Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer

PharmacoEconomics, 2018-04, Vol.36 (4), p.495-504

2018

Link zum Volltext

Verfügbarkeit prüfen

How does cumulative evidence from older adult-specific trials influence clinical practice? A difference-in-differences analysis in early-stage breast cancer

Contemporary clinical trials, 2023-05, Vol.128, p.107135-107135, Article 107135

2023

Link zum Volltext

Verfügbarkeit prüfen

Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials

JNCI : Journal of the National Cancer Institute, 2016-02, Vol.108 (2), p.djv324

2016

Link zum Volltext

Verfügbarkeit prüfen

Evaluating Policies of Expanding Versus Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis Framework

Value in health, 2024-04, Vol.27 (4), p.433-440

2024

Link zum Volltext

Verfügbarkeit prüfen

Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study

Cancer medicine (Malden, MA), 2018-09, Vol.7 (9), p.4251-4260

2018

Link zum Volltext

Verfügbarkeit prüfen

The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study

Value in health, 2019-02, Vol.22 (2), p.194-202

2019

Link zum Volltext

Verfügbarkeit prüfen

Use of real-world evidence in economic assessments of pharmaceuticals in the United States

Journal of managed care & specialty pharmacy, 2021-01, Vol.27 (1), p.5

2021

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome

PharmacoEconomics, 2020-11, Vol.38 (11), p.1237-1245

2020

Link zum Volltext

Verfügbarkeit prüfen

Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?

PharmacoEconomics, 2023-03, Vol.41 (3), p.321-327

2023

Link zum Volltext

Verfügbarkeit prüfen

Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer

The American journal of managed care, 2022-01, Vol.28 (2 Suppl), p.S26-S32

2022

Link zum Volltext

Verfügbarkeit prüfen

Assessing Payers’ Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment

Value in health, 2022-03, Vol.25 (3), p.443-450

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 139

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(129)
Mit Volltextzugriff
(111)

Publikationsform

Artikel
(138)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

Real-world treatment patterns and economic burden of post-cataract macular edema

Economic Evaluation of Tocilizumab Monotherapy Compared to Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis

Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy

HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales

Performance-Based Risk-Sharing Arrangements: An Updated International Review

Performance-based risk-sharing arrangements for devices and diagnostics in the United States: a systematic review

How Much Does the US Public Value Equity in Health? A Systematic Review

Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing

Estimating the Cost-Effectiveness of OnabotulinumtoxinA for Neurogenic Detrusor Overactivity in the United States

The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer

Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study

Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study

Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis

Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer

How does cumulative evidence from older adult-specific trials influence clinical practice? A difference-in-differences analysis in early-stage breast cancer

Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials

Evaluating Policies of Expanding Versus Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis Framework

Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study

The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study

Use of real-world evidence in economic assessments of pharmaceuticals in the United States

Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome

Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?

Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer

Assessing Payers’ Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment

Suchergebnisse filtern